🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10953209

    Treating tumors using TTFields combined with a PARP inhibitor

    The Board of Regents of the University of Texas System · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10947198

    Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroarotinoids as anti-cancer agents

    The Board of Regents for Oklahoma State University · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10946106

    Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen

    The Regents of the University of California · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10946045

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10946005

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10946000

    Method for treating cancer with combination therapy

    RedHill Biopharma Ltd. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10946044

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10941128

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10934547

    Use of trinucleotide repeat RNAs to treat cancer

    Northwestern University · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10933076

    Crocin-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10934550

    Immunotherapy of cancer

    Phio Pharmaceuticals Corp. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10925971

    Methods of treating PRLR positive breast cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10927088

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10918666

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10912797

    Tumor infiltrating lymphocytes and methods of therapy

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10912776

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10912741

    Prevention of liver cancer with safranal-based formulations

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10899710

    Pyridines and their use in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10898478

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10894044

    Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10894063

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10888618

    Method of treating cancer

    Intensity Therapeutics, Inc. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10889637

    Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies

    The Board of Regents of the University of Texas System · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10881646

    Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

    Biomed Valley Discoveries, Inc. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10881689

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10883994

    Identification of cancer stem cells markers and use of same for diagnosis and treatment

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10881653

    Tricyclic compounds and their use in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10874610

    Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer

    Northwestern University · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10874631

    Altertoxin II as a selective inhibitor of Ewing family of tumor cells

    The Board of Regents of the University of Texas System · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10875903

    Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10870854

    Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

    The Board of Regents of the University of Texas System · Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10869863

    Multi-arm polymeric targeting anti-cancer conjugate

    BrightGene Bio-Medical Technology Co., Ltd. · Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10857184

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10857225

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics, Inc. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10857174

    Morpholino oligonucleotides useful in cancer treatment

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10849960

    Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10849912

    Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10849875

    Cancer specific lipid targeted peptidomimetics

    The Board of Regents of the University of Texas System · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10842835

    Oncolytic vaccinia virus mutants and using same for cancer treatment

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10844052

    LLS compounds for treatment of cancer

    The Regents of the University of California · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10845366

    Predictive markers for polyamine inhibitor cancer therapies

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10835604

    Biomaterials for combined radiotherapy and immunotherapy of cancer

    Northwestern University · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10836759

    Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10828255

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    The Regents of the University of California · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10828280

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10822588

    Agents and methods to elicit anti-tumor immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10821163

    Process for the production of a DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.